The management of malignant hypercalcaemia

Drugs

Volumn 52, Issue 6, 1996, Pages 837-848

  Watters, Julie ^a   Gerrard, Georgina ^a   Dodwell, David ^a  

^a Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; GALLIUM NITRATE; MITHRAMYCIN; PAMIDRONIC ACID; PHOSPHATE;

ABDOMINAL CRAMP; CANCER; CLINICAL PRACTICE; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; FEVER; FLUID THERAPY; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LIVER DISEASE; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPTOMATOLOGY; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

EID: 0029826473     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652060-00005     Document Type: Review

References (59)

1. Anon. Treating cancer-associated hypercalcaemia. Drug Ther Bull 1990; 20: 85-7
2. Goodwin JS, Atluru D, Sierakowski S, et al. Mechanism of action of glucocorticosteroids: inhibition of T cell proliferation and interleukin 2 production by hydrocortisone is reversed by leukotriene B4. J Clin Invest 1986; 77: 1244-50
3. Bilesikian JP. Management of acute hypercalcaemia. N Engl J Med 1992; 326: 1196-203
4. Percival RC, Yates AJP, Gray RES, et al. Role of glucocorticoids in the management of malignant hypercalcaemia [letter]. BMJ 1984; 289: 287
5. Ralston SH, Gardner MD, Dryburgh FJ, et al. Comparison of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet 1985; 11: 907-10
6. Thurlimann B, Waldburger R, Senn HJ, et al. Plicamycin and pamidronate in symptomatic tumour-related hypercalcaemia: a prospective randomized crossover trial. Ann Oncol 1992; 3: 619-23
7. Green L, Donehower RC. Hepatic toxicity of low doses of mithramycin in hypercalcemia. Cancer Treat Rep 1984; 68: 1379-81
8. Ostenstad B, Andersen OK. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcaemia. Acta Oncol 1992; 31: 861-4
9. Clissold SP, Fitton A, Chrisp P. Intranasal salmon calcitonin: a review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging. Drugs Aging 1991; 1: 405-23
10. Hosking DJ, Gilson D. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. Q J Med 1984; 211: 359-68
11. Wisneski LA. Salmon calcitonin in the acute management of hypercalcaemia. Calcif Tissue Int 1990; 46 Suppl.: S26-30
12. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MLL, et al. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986; 1: 27-39
13. Reitsma PH, Bijvoet OLM, Potokar M, et al. Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-biphosphonate (APD). Calcif Tissue Int 1983; 35: 357-61
14. Dodwell DJ, Howell A, Ford J. Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. Br J Cancer 1990; 61: 123-5
15. Thiebaud D, Jaeger Ph, Jacquet AF, et al. Dose-response in the treatment of hypercalcaemia and malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 1988; 6: 762-8
16. Body JJ, Dumon JC. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. Ann Oncol 1994; 5: 359-63
17. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcaemia of malignancy: comparison of 30-, 60-, 90-mg dosages. Am J Med 1993; 95: 297-304
18. Davis JRE, Health DA. Comparison of different dose regimes of aminohydroxypropylidene-1, 1-bisphosphonate (APD) in hypercalcaemia of malignancy. Br J Clin Pharmacol 1989; 28: 269-74
19. Daley-Yates PT, Dodwell DJ, Pongchaidecha M, et al. The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 1991; 49 (6): 37-41
20. Dodwell DJ, Howell A, Morton AR, et al. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. Postgrad Med J 1992; 68: 434-9
21. Morton AR, Cantrill JA, Craig AE, et al. Single dose versus daily intravenous aminohydroxypropylidene diphosphonate (APD) for the hypercalcaemia of malignancy. BMJ 1988; 296: 811-4
22. Cantwell BMJ, Harris AL. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer. BMJ 1987; 294: 467-9
23. Wimalawansa SJ. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. Clin Endocrinol Metab 1994; 41: 591-5
24. Body JJ, Borkowski A, Cleeran A, et al. Treatment of malignancy-associated hypercalcaemia with intravenous aminohydroxypropylidine diphosphonate. J Clin Oncol 1986; 4: 1177-83
25. Ralston SH, Alzaid AA, Gallacher SJ, et al. Clinical experience with aminohydroxypropylidine bisphosphonate (APD) in the management of cancer associated hypercalcaemia. Q J Med 1988; 69: 825-34
26. Gallacher SJ, Ralston SH, Pael U, et al. Side effects of pamidronate. Lancet 1989; II: 42-3
27. Jodrell DI, Iveson TJ, Smith IE. Symptomatic hypocalcemia after treatment with high-dose aminohydroxypropylidene diphosphonate [letter]. Lancet 1987; I: 622
28. Body JJ, Pot M, Borkowski A, et al. Dose/response study of aminohydroxypropylidene bisphosphonate in tumour-associated hypercalcaemia. Am J Med 1987; 82: 957-63
29. Pentikainen PJ, Elomaa I, Nurmi AK, et al. Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther Toxicol 1989; 27: 222-8
30. O'Rourke NP, McCloskey EV, Vasikaran S, et al. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 1993; 67: 560-3
31. Kanis JA, McCloskey EV, Paterson AHG. Use of diphosphonates in hypercalcaemia due to malignancy. Lancet 1990; 335: 170-1
32. Bonjour JP, Philippe J, Guelpa G, et al. Bone and renal components in hypercalcaemia of malignancy and responses to a single infusion of clodronate. Bone 1988; 9: 123-30
33. Adami S, Bolzicco GP, Rizzo A, et al. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcaemia of malignancy. Bone Miner 1987; 2: 395-404
34. O'Rourke, McCloskey EV, Neugebauer G, et al. Renal and non-renal clearance of clodronate in patients with malignancy and renal impairment. Drug Invest 1994; 7 (1): 26-33
35. Ljunghall S, Rastad J, Akerstrom G. Comparative effects of calcitonin and clodronate in hypercalcaemia. Bone 1987; 8 Suppl. 1: S79-83
36. Powell JH, DeMark BR. Clinical Pharmacokinetics of diphosphonates. Bone Resorption, Metastasis and Diphosphonates 1985: 41-9
37. Singer FR, Ritch PS, Lad TE, et al. Treatment of hypercalcaemia of malignancy with intravenous etidronate. Arch Intern Med 1991; 151: 471-6
38. Patel S, Lyons AR, Hosking DJ. Drugs used in the treatment of metabolic bone disease: clinical pharmacology and therapeutic use. Drugs 1993; 46 (4): 594-617
39. Flores JF, Rude RK, Chapman RA, et al. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcaemia of malignancy. Cancer 1994; 73: 2527-34
40. Warrell RP, Murphy WK, Schulman P, et al. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcaemia. J Clin Oncol 1991; 9: 1467-75
41. Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer-related hypercalcaemia. Lancet 1989; 1: 1180-2
42. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcaemia. J Clin Oncol 1992; 10: 134-42
43. Warrell Jr RP. Clinical trials of gallium nitrate in patients with cancer-related hypercalcaemia. Semin Oncol 1991; 18 Suppl. 5: 26-31
44. Blumenthal NC, Cosma V, Levine S. Effect of gallium on the in vitro formation, growth and solubility of hydroxyapatite. Calcif Tissue Int 1989; 45: 81-7
45. Repo MA, Bockman RS, Betts F, et al. Effect of gallium on bone mineral properties. Calcif Tissue Int 1988; 43: 300-6
46. Warrell RP, Bockman RS. Gallium in the treatment of hypercalcaemia and hone metastasis. Important Adv Oncol 1989: 205-20
47. Warrell Jr RP, Alcock NW, Bockman RS. Gallium nitrate inhibits accelerated hone turnover in patients with bone metastases. J Clin Oncol 1987; 5: 292-8
48. Bockman RS, Boskey A, Blumenthal NC, et al. Gallium increases hone calcium and crystallite perfection of hydroxyapatite. Calcif Tissue Int 1986; 39: 376-81
49. Guidon PT, Bockman RS. Gallium nitrate initiates expression of early and late genes responsible for bone formation [abstract]. J Bone Miner Res 1990; Suppl.2: S91
50. Bockman RS. Studies on the mechanism of action of gallium nitrate. Semin Oncol 1991; 18 Suppl. 5: 21-5
51. Wakeley GK, Brown D, Garant J, et al. Gallium inhibits not only bone resorption but also bone formation in vivo, possibly by an indirect mechanism [abstract]. Clin Res 1986; 34: 689A
52. Ho DH, Lin JR, Brown NS, et al. Bioavailability of gallium nitrate [abstract]. Eur J Pharmacol 1990; 183: 1200
53. Kinirons MT. Newer agents for the treatment of malignant hypercalcaemia. Am J Med Sci 1993; 305: 403-6
54. Hall SW, Yeung K, Benjamin RS, et al. Kinetics of gallium nitrate, a new anticancer agent. Clin Pharmacol Ther 1979; 25: 82-7
55. Krakoff IH, Newman RA, Goldbert RS. Clinical toxicologic and pharmacologic studies of gallium nitrate. Cancer 1979; 44: 1722-7
56. Kelsen DP, Alcock N, Yeh S, et al. Pharmacokinetics of gallium nitrate in man. Cancer 1980; 46: 2009-13
57. Warrell RP, Skelos A, Alcock NW, et al. Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis. Cancer Res 1986; 46: 4208-12
58. Warrell RP, Israel R, Frisone M, et al. Gallium nitrate for acute treatment of cancer-related hypercalcemia - a randomized, double-blind comparison of calcitonin. Ann Intern Med 1988; 108: 669-74
59. Fleisch H. Chemistry and mechanisms of action of bisphosphonates. In: Garattini S, editor. Bone resorption, metastasis and diphosphonates. New York: Raven Press, 1985: 33-40